Auron Therapeutics, Inc.
Small molecule therapeutics that modulate cell state to treat cancer
- Sector
- Biotech
- Headquarters
- NEWTON, MA
- Founded
- 2018
- Latest Form D
- $7.1M, Aug 2026
- Total capital
- $62.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $62.6M
- 5 Form D · last Aug 2026
- 2 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 17 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$7.1M
- Private capital raisedForm D · SEC · 4th filing$13.4M
- Private capital raisedForm D · SEC · 3rd filing$26M
- Private capital raisedForm D · SEC · 2nd filing$15.4M
- Private capital raisedForm D · SEC · 1st filing$660K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Alexandra CantleyDirectorNamed in SEC Form D filings
- Alon Duncan LazarusDirectorNamed in SEC Form D filings
- Anna Duncan FrenchDirectorNamed in SEC Form D filings
- Briggs Duncan MorrisonDirectorNamed in SEC Form D filings
- Christopher Duncan GuiffreExecutive OfficerNamed in SEC Form D filings
- Eric Duncan ShiozakiDirectorNamed in SEC Form D filings
Show all 12 people
- Isaac CiechanoverDirectorNamed in SEC Form D filings
- John Duncan HiggonsDirectorNamed in SEC Form D filings
- Katharine YenExecutive Officer, DirectorNamed in SEC Form D filings
- Pini Duncan OrbachDirectorNamed in SEC Form D filings
- Serge Duncan MesserlianDirectorNamed in SEC Form D filings
- Victoria Duncan RichonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 17- PendingTechnologies Targeting Cell StatesUSPTOApplication 63561294
- PendingTechnologies Targeting Cell StatesUSPTOApplication 19475567
- PendingTechnologies Targeting Cell StatesUSPTOApplication PCTUS2025050152
Show all 17 patent records
- Technologies Targeting Cell StatesApplication 63561294Pending
- Technologies Targeting Cell StatesApplication 19475567Pending
- Technologies Targeting Cell StatesApplication PCTUS2025050152Pending
- Technologies For Modulating Citk And Cell StatesApplication PCTUS2025027645Pending
- Technologies Targeting Cell StatesApplication 63780062Pending
- Technologies Targeting Cell StatesApplication 63774712Pending
- Technologies Targeting Cell StatesApplication 63716640Pending
- Technologies Targeting Cell StatesApplication 63711114Pending
- Technologies Targeting Cell StatesApplication 63705015Pending
- Technologies For Modulating Citk And Cell StatesApplication 63642519Pending
- Technologies For Modulating Citk And Cell StatesApplication 63642513Pending
- Technologies Targeting Cell StatesApplication PCTUS2024025468Pending
- Technologies Targeting Cell StatesApplication 63575594Pending
- Heterocyclic Phenyl Compounds As KAT2 DegradersApplication PCTUS2023031835Pending
- Heterocyclic Phenyl Compounds As KAT2 DegradersApplication 63460764Pending
- Heterocyclic Phenyl Compounds As KAT2 DegradersApplication 63403401Pending
- Pyridazinon Derivatives As KAT2 Degraders For The Treatment Of Proliferative DisordersApplication 19108040Pending
Related companies, and why
- ELIXIRGEN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Fountain Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Appello Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Redona Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- EPALEX CorpSimilar federal contract value in Biotech · null in contracts
- Cybrexa Holding Company, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .